Company news
Cantargia Ab (OMXSTO:CANTA) news
Cantargia Ab news releases on 6ix. Latest, Aug 4, 2026: Cantargia to Host Q2 2026 Interim Results Conference Call
Press releases & updates
Cantargia to Host Q2 2026 Interim Results Conference Call
August 4, 2026
Cantargia : Cantargia Announces Changes in Number of Shares and Votes
July 31, 2026
Cantargia Announces Changes in Number of Shares and Votes
July 31, 2026
Cantargia Announces Publication of Data Supporting IL1RAP as a Therapeutic Target and Predictive Biomarker in PDAC
June 26, 2026
Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital
June 23, 2026
Cantargia publishes Information Document regarding Rights Issue of Shares
June 5, 2026
Cantargia AB to Host Webcast Covering Rights Issue, Loan Agreement, and Strategic Priorities
May 28, 2026
Bulletin from the Annual General Meeting in Cantargia AB (publ)
May 21, 2026
Cantargia Publishes Interim Report for The First Quarter of 2026
May 19, 2026
Cantargia Announces Early Results from Trial of Nadunolimab in MDS and AML
April 27, 2026
Notice of Annual General Meeting in Cantargia AB (publ)
April 17, 2026
Cantargia Publishes Annual Report 2025
April 17, 2026
Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference
March 5, 2026
Cantargia to Participate in TD Cowen's Annual Healthcare Conference
February 23, 2026
Cantargia Publishes Full Year Report 2025
February 20, 2026
Invitation to the Presentation of Cantargia's Annual Results for 2025
February 6, 2026
Cantargia to Participate at Leerink Partners Global Healthcare Conference
January 28, 2026
Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study
January 23, 2026
Cantargia Provides Update on Overall Survival Data from TRIFOUR
December 5, 2025
Cantargia Publishes Interim Report for January to September 2025
November 19, 2025
Cantargia Presents Nomination Committee Ahead of 2026 AGM
November 12, 2025
Invitation to the Presentation of Cantargia's Interim Report January-September 2025
November 5, 2025
Cantargia to Participate in Upcoming Conferences
October 23, 2025
Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer
October 2, 2025
Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC
September 30, 2025
Cantargia Closes the Acquisition of CAN10 by Otsuka
September 11, 2025
Cantargia Granted Important US Patent for Nadunolimab
August 27, 2025
Cantargia Publishes Half-Year Report 2025
August 21, 2025
Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer
August 18, 2025
Invitation to the Presentation of Cantargia's H1 2025 Report
August 12, 2025
Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer (TNBC)
July 17, 2025
Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer
July 16, 2025
Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical
July 15, 2025
Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans
June 17, 2025
Cantargia’s Nadunolimab Aantibody Awarded US FDA Fast Track Designation
June 11, 2025
Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation
May 19, 2025
Bulletin from the Annual General Meeting in Cantargia AB
May 15, 2025
Cantargia Publishes Interim Report for the First Quarter of 2025
May 13, 2025
Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2
May 12, 2025
Cantargia’s Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors
May 6, 2025
Invitation to the Presentation of Cantargia's Interim Report for Q1 2025
April 29, 2025
Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10
April 29, 2025
Cantargia Announces the Publication of Preclinical Data Highlighting Nadunolimab's Potential to Counteract Tumor-Driven Systemic Immunosuppression
April 28, 2025
Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate (ADC) at a Major Cancer Conference
April 25, 2025
Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy (CIPN) at AACR
April 25, 2025